8-K: BioRestorative Therapies to Present at 36th Annual ROTH Conference

BioRestorative Therapies will participate in the 36th Annual ROTH Conference, with CEO Lance Alstodt scheduled for a fireside chat.

Summary

• BioRestorative Therapies, a clinical-stage company focused on stem cell-based therapies, will be participating in the 36th Annual ROTH Conference from March 17-19, 2024.
• The company's CEO, Lance Alstodt, will participate in a fireside chat on March 18, 2024, at 12:00 PM PDT.
• The fireside chat will be broadcast live and archived on the company's website.
• BioRestorative's management team will also hold one-on-one meetings with investors during the conference.
• The company is developing cell-based therapies for disc/spine disease and metabolic disorders.
• Their lead therapy, BRTX-100, uses a patient's own stem cells to treat lower back pain from degenerative disc disease.
• They are also developing a therapy called ThermoStem, which uses brown fat stem cells to target obesity and metabolic disorders.

Sentiment

Score: 7

Explanation: The document is a positive announcement of investor engagement and progress in clinical trials, but it also includes standard risk disclosures.

Positives

• The company is actively engaging with investors through the ROTH Conference.
• The company has two core programs in development, addressing significant medical needs.
• BRTX-100 is in Phase 2 clinical trials, indicating progress in its development.
• The company is exploring innovative approaches to treating metabolic disorders with ThermoStem.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's success is dependent on the outcome of clinical trials and regulatory approvals.

Future Outlook

The company will continue to develop its cell-based therapies and engage with investors.

Management Comments

• Lance Alstodt, CEO of BioRestorative Therapies, is scheduled to participate in a fireside chat at the ROTH Conference.

Industry Context

The company's participation in the ROTH Conference highlights the growing interest in stem cell-based therapies and their potential to address unmet medical needs.

Comparison to Industry Standards

• BioRestorative Therapies is focused on developing cell-based therapies, which is a growing area in the biotechnology industry.
• Other companies in the space include Mesoblast, which is developing cell therapies for inflammatory diseases, and Vericel, which focuses on cell therapies for cartilage repair.
• The company's approach of using autologous stem cells for disc/spine disease is similar to other companies in the regenerative medicine space.
• The development of brown fat-derived stem cells for metabolic disorders is a novel approach that could differentiate BioRestorative from its competitors.

Stakeholder Impact

• Shareholders will be informed about the company's progress and future plans.
• Potential investors will have the opportunity to learn more about the company.
• Employees will be aware of the company's engagement with the investment community.

Next Steps

• BioRestorative Therapies will participate in the ROTH Conference from March 17-19, 2024.
• The company will conduct a fireside chat on March 18, 2024.
• The company will hold one-on-one meetings with investors during the conference.

Key Dates

Keywords

stem cell therapy, clinical stage, biotechnology, BRTX-100, ThermoStem, ROTH Conference, degenerative disc disease, metabolic disorders, brown fat, investor relations